Ibrutinib in Combination With Rituximab for Indolent Clinical Forms of Mantle Cell Lymphoma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Journal of Clinical Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Ibrutinib in Combination With Rituximab for Indolent Clinical Forms of Mantle Cell Lymphoma (IMCL-2015): A Multicenter, Open-Label, Single-Arm, Phase II Trial
J. Clin. Oncol 2022 Jan 14;[EPub Ahead of Print], E Giné, F de la Cruz, A Jiménez Ubieto, J López Jimenez, A Martín García-Sancho, MJ Terol, E González Barca, M Casanova, A de la Fuente, A Marín-Niebla, A Muntañola, TJ González-López, M Aymerich, X Setoain, M Cortés-Romera, A Rotger, S Rodríguez, A Medina Herrera, R García Sanz, F Nadeu, S Beà, E Campo, A López-GuillermoFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.